Replay available

OXFORD BIOMEDICA PLC (OXB) — Investor Presentation

Investor Presentation hosted by OXFORD BIOMEDICA PLC (LSE: OXB) on Investor Meet Company. Replay available.

Thu, September 24, 2026 at 6:15 AMendedReplay
OXFORD BIOMEDICA PLC (OXB) — Investor Presentation

Investor webinar replay

Meeting Overview The Oxford Biomedica PLC investor presentation focused on the company's interim results for the first half of 2026. Key highlights included updates on commercial performance, client growth, and the overall market environment for cell and gene therapies. Key Discussion Points - Introduction of the Oxford Biomedica team and the purpose of the meeting. - Overview of the company's role in cell and gene therapy, emphasizing the importance of viral vectors. - Presentation of interim results, reiterating guidance for 2026 and growth expectations for 2027. - Discussion of the strong commercial momentum, including the signing of 22 new clients in the first half of 2026. - Highlighting the increase in pipeline value to $713 million and contracted orders growth. - Expansion of global footprint with facilities in the UK, US, and France. - Introduction of the new Chief Operating Officer, Eric Schmidhäuser. - Positive market indicators including new approvals, clinical data, and ...

Latest press releases

Companies on this event

Featured Presenters

Dr. Frank Mathias

CEO at OXFORD BIOMEDICA PLC

Dr. Lucinda Crabtree

CFO at OXFORD BIOMEDICA PLC

Dr. Sébastien Ribault

CBO at OXFORD BIOMEDICA PLC

Replay transcript excerpt

Speaker 1: Good morning and welcome to the Oxford Biomedica PLC investor presentation. Throughout this recorded meeting investors will be in listen-only mode. Questions are encouraged to be submitted anytime by the Q&A tab situated in the right-hand corner of your screen. Just simply type in your question and press send. The company may not be in a position to answer every question received during the meeting itself. However, we can review all questions submitted and publish responses where appropriate to do so. Before we begin, we'd like to submit the following poll. I'd now like to hand you over to the Oxford Biomedica PRC team. Good morning. Speaker 2: Good morning, everyone. Speaker 2: I'm Frank Mathias, CEO of the company. So thank you, Speaker 2: all of you, for joining us today in this investor Speaker 2: presentation, which is, I have to say, the 1st on this platform. So I'm joined by our Chief Financial Officer, Dr. Lucie Créptry, Speaker 2: and we have also with us our Chief Business Officer, Speaker 2: Dr. Sébastien Ribaud. Speaker 2: I'm really delighted Speaker 2: to present to you today and we will be discussing Speaker 2: our interim results for the 1st Speaker 2: 0.5 of 2026. Speaker 2: So Speaker 2: I'm aware that probably Speaker 2: at least some of you have seen our full briefing earlier this week, it was on Tuesday. Speaker 2: So we will just provide you with a Speaker 2: more shortened presentation, Speaker 2: but Speaker 2: this gives us more opportunity Speaker 2: to be able Speaker 2: to answer all your questions. Speaker 2: So if you want to look for the full briefing, Speaker 2: you can watch out on our Speaker 2: website. Speaker 2: If I can go to the next slide. Speaker 2: Please consider the disclaimer as always. This is my next slide. Sp...

More from Oxford Biomedica Plc